Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?

References

• United States Renal Data Systems2011 Annual Data ReportBethesda, MDNational Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases2011
   Google Scholar
• Kidney Disease Outcomes Quality InitiativeClinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin targetAm J Kidney Dis20075047153017720528
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, Centers for Medicare and Medicaid Services Medicare and Medicaid ProgramsConditions for Coverage for End-Stage Renal Disease FacilitiesFinal Rule. 42 CFR Parts 405, 410, 413, 414, 488, and 494 Available from: http://www.cms.gov/CFCsAndCoPs/downloads/ESRDfinalrule0415.pdfAccessed January 27, 2012
   Google Scholar
• RobinsonBMFullerDSBieberBATurenneMNPisoniRLThe DOPPS Practice Monitor for US dialysis care: trends through Apr 2011Am J Kidney Dis20125930931222169621
   PubMed Web of Science ®Google Scholar
• CardoneKEFoxBMeolaSEffects of the ESRD Medicare Bundling Rule on Anemia Management in Private Dialysis UnitsPresented at the American Society of Nephrology Renal WeekNovember 8–13, 2011Philadelphia, PA
   Google Scholar
• SinghAKSzczechLTangKLCHOIR InvestigatorsCorrection of anemia with epoetin alfa in chronic kidney diseaseN Engl J Med20063552085209817108343
   PubMed Web of Science ®Google Scholar
• DrüekeTBLocatelliFClyneNCREATE InvestigatorsNormalization of hemoglobin level in patients with chronic kidney disease and anemiaN Engl J Med20063552071208417108342
   PubMed Web of Science ®Google Scholar
• PfefferMABurdmannEAChenCYTREAT InvestigatorsA trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseN Engl J Med20093612019203219880844
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes Anemia Work GroupKDIGO clinical practice guideline for anemia in chronic kidney diseaseKidney Int Suppl20122279335
   Web of Science ®Google Scholar
• AlbaramkiJHodsonEMCraigJCWebsterACParenteral versus oral iron therapy for adults and children with chronic kidney diseaseCochrane Database Syst Rev20121CD00785722258974
   PubMed Web of Science ®Google Scholar
• BhandariSNaudeerSImproving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choiceJ Eval Clin Pract200814996100118785894
   PubMed Web of Science ®Google Scholar
• GilbertsonDTEbbenJPFoleyRNHemoglobin level variability: associations with mortalityClin J Am Soc Nephrol2008313313818045862
   PubMed Web of Science ®Google Scholar
• de FranciscoALStenvinkelPVaulontSInflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsivenessNDT Plus20092 Suppl 1i18i2619461856
   PubMedGoogle Scholar
• KanbayMPerazellaMAKasapogluBKorogluMCovicAErythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and managementBlood Purif20102911219816014
   PubMed Web of Science ®Google Scholar
• NemethEGanzTThe role of hepcidin in iron metabolismActa Haematol20091222–3788619907144
   PubMed Web of Science ®Google Scholar
• ZaritskyJYoungBWangH-JHepcidin-A potential biomarker for iron status in chronic kidney diseaseClin J Am Soc Nephrol200941051105619406957
   PubMed Web of Science ®Google Scholar
• VilelaEMBastosJAFernandesNFerreiraAPChaoubahABastosMGTreatment of chronic periodontitis decreases serum prohepcidin levels in patients with chronic kidney diseaseClinics (Sao Paolo)201166657662
   PubMed Web of Science ®Google Scholar
• FordKIEbyCSScottMGCoyneDWIntra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patientsKidney Int20107876977320668427
   PubMed Web of Science ®Google Scholar
• TessitoreNGirelliDCampostriniNHepcidin is not a useful biomarker for iron needs in hemodialysis patients on maintenance erythropoiesis-stimulating agentsNephrol Dial Transplant2010253996400220538788
   PubMed Web of Science ®Google Scholar
• SpinowitzBSSchwenkMHJacobsPMThe safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patientsKidney Int2005681801180716164657
   PubMed Web of Science ®Google Scholar
• BalakrishnanVSRaoMKauszATPhysicochemical properties of ferumoxytol, a new intravenous iron preparationEur J Clin Invest20093948949619397688
   PubMed Web of Science ®Google Scholar
• Feraheme™ (ferumoxytol) injection prescribing informationLexington, MAAMAG Pharmaceuticals Inc2010
   Google Scholar
• JahnMRAndreasenHSFuttererSA comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implicationsEur J Pharm Biopharm20117848049121439379
   PubMed Web of Science ®Google Scholar
• SeligmanPADahlNVStrobosJSingle-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjectsPharmacotherapy20042457458315162891
   PubMed Web of Science ®Google Scholar
• DanielsonBGSalmonsonTDerendorfHGeisserPPharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteersArzneimittelforschung1996466156218767353
   PubMed Web of Science ®Google Scholar
• McLachlanSJMorrisMRLucasMAPhase I clinical evaluation of a new iron oxide MR contrast agentJ Magn Reson Imaging199443013078061425
   PubMed Web of Science ®Google Scholar
• PaiABNielsenJCKauszAMillerPOwenJSPlasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjectsClin Pharmacol Ther20108823724220592725
   PubMed Web of Science ®Google Scholar
• LandryRJacobsPMDavisRShenoudaMBoltonWKPharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patientsAm J Nephrol20052540041016088081
   PubMed Web of Science ®Google Scholar
• SpinowitzBSKauszATBaptistaJFerumoxytol for treating iron deficiency anemia in CKDJ Am Soc Nephrol2008191599160518525001
   PubMed Web of Science ®Google Scholar
• ProvenzanoRSchillerBRaoMCoyneDBrennerLPereiraBJFerumoxytol as an intravenous iron replacement therapy in hemodialysis patientsClin J Am Soc Nephrol2009438639319176796
   PubMed Web of Science ®Google Scholar
• StraussWLiJMcLaughlinDifferential hemoglobin response following treatment with two IV irons in patients on hemodialysis or with more severe anemia: results from the ferumoxytol compared to iron sucrose trial (FIRST)Abstract 49 presented at the National Kidney Foundation Spring Clinical MeetingMay 9–13, 2012Washington, DC
   Google Scholar
• SinghAPatelTHertelJBernardoMKauszABrennerLSafety of ferumoxytol in patients with anemia and CKDAm J Kidney Dis20085290799518824288
   PubMed Web of Science ®Google Scholar
• BailieGRComparison of rates of reported adverse events associated with IV iron products in the United StatesAm J Health Syst Pharm20126931032022302256
   PubMed Web of Science ®Google Scholar
• SantoshSPodarallaPMillerBAnaphylaxis with elevated tryptase after administration of intravenous ferumoxytolNDT Plus201013221314
   Google Scholar
• AseroRMultiple drug allergy syndrome: a distinct clinical entityCurr Allergy Rep20011182211899280
   PubMedGoogle Scholar
• GromanEVPaulKGFrigoTBBenegeleHLewisJMHeat stable colloidal iron oxides coated with reduced carbohydrates and carbohydrate derivativesUS Patent 6,599,4987292007United States
   Google Scholar
• SimonGHvon Vopelius-FeldtJFuYUltrasmall supra-paramagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytolInvest Radiol200641455116355039
   PubMed Web of Science ®Google Scholar
• RosnerMHAuerbachMFerumoxytol for the treatment of iron deficiencyExpert Rev Hematol2011439940621801130
   PubMed Web of Science ®Google Scholar
• HimmelfarbJStenvinkelPIkizlerTAHakimRMThe elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney Int2002621524153812371953
   PubMed Web of Science ®Google Scholar
• Del VecchioLLocatelliFCariniMWhat we know about oxidative stress in patients with chronic kidney disease on dialysis clinical effects, potential treatment, and preventionSemin Dial201124566421299632
   PubMed Web of Science ®Google Scholar
• DanielsonBGStructure, chemistry, and pharmacokinetics of intravenous iron agentsJ Am Soc Nephrol200415S93S9815585603
   PubMed Web of Science ®Google Scholar
• JomovaKValkoMImportance of iron chelation in free radical-induced oxidative stress and human diseaseCurr Pharm Des2011173460347321902663
   PubMed Web of Science ®Google Scholar
• PaiABBoydAVMcQuadeCRHarfordANorenbergJPZagerPGComparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and sucrose in patients undergoing hemodialysisPharmacotherapy20072734335017316146
   PubMed Web of Science ®Google Scholar
• GeisserPBaerMSchaubEStructure/histotoxicity relationship of parenteral iron preparationsArzneimittelforschung199242143914521288508
   PubMed Web of Science ®Google Scholar
• TernesNScheiber-MojdehkarBLandgrafGGoldenbergHSturmBIron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophagesNephrol Dial Transplant2007222824283017556418
   PubMed Web of Science ®Google Scholar
• JohnsonACBeckerKZagerRAParenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injuryAm J Physiol Renal Physiol2010299F426F43520504881
   PubMed Web of Science ®Google Scholar
• ToblliJECaoGOliveriLAngerosaMAssessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical modelArzneimittelforschung2011639941021899208
   PubMed Web of Science ®Google Scholar
• AgarwalRLeeheyDJOlsenSMDahlNVProteinuria induced by parenteral iron in chronic kidney disease – a comparative randomized controlled trialClin J Am Soc Nephrol2011611412120876669
   PubMed Web of Science ®Google Scholar
• WeisslederRStarkDDEngelstadBLSupermagnetic iron oxide: pharmacokinetics and toxicityAJR Am J Roentgenol19891521671732783272
   PubMed Web of Science ®Google Scholar
• TsuchiyaKNittaNSonodaAHistological study of the biodynamics of iron oxide nanoparticles with different diametersInt J Nanomedicine201161587159421845049
   PubMed Web of Science ®Google Scholar
• FunkFRylePCancliniCNeiserSGeisserPThe new generation intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltoseArzneimittelforschung20106034535320648926
   PubMed Web of Science ®Google Scholar